Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The report highlights that the pharmaceutical sector is showing resilience, with a focus on capturing opportunities from companies that can deliver on their growth potential. The report suggests that investors should continue to allocate to pharmaceutical bottom assets as fund holdings have returned to a low level [3][10] - The report indicates that the A-share funds' top ten holdings in the pharmaceutical sector account for 9.15%, a decrease of 1.93 percentage points from the previous period. Excluding pharmaceutical funds, the allocation drops to 3.43%, down 1.39 percentage points [3][10] - The report emphasizes the strong performance of certain pharmaceutical companies, particularly in innovative drugs and upstream life sciences, with notable profit growth forecasts for companies like Zhaoyan New Drug and Kangchen Pharmaceutical [3][10] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 6.66% compared to the CSI 300's 1.57% since the beginning of 2026, indicating a 5.10 percentage point advantage [14] - Recent performance shows a mixed trend, with pharmaceutical commercial, traditional Chinese medicine, and medical devices showing positive growth, while chemical pharmaceuticals and medical services have declined [10][14] Valuation Metrics - The current valuation of the pharmaceutical sector is at 23.3 times PE based on 2026 earnings forecasts, which is a premium of 11.3% compared to the overall A-share market (excluding financials) at approximately 21.0 times PE [17] - Using the TTM valuation method, the pharmaceutical sector is valued at 30.3 times PE, which is below its historical average of 34.9 times PE, indicating a relative premium of 11.2% over the broader market [17] Recommended Stocks - Key recommended stocks include WuXi Biologics, Sangfor Technologies, Tigermed, and others, with an average increase of 13.41% in January, outperforming the pharmaceutical sector by 6.74 percentage points [26][27] - The report notes that the top ten pharmaceutical stocks held by public funds include companies like Hengrui Medicine and WuXi AppTec, with a strong preference for innovative drugs and leading players in niche markets [3][10]

Key Points - The article highlights two critical time points in 2025: the trading opportunities arising from external risk resolution in early April and the allocation opportunities following the synchronization of the economic and policy cycles between China and the U.S. in mid-year [2][3] - The technology sector is expected to be a strong focus for investment in April and May, following significant adjustments in March and potential catalysts [3] - The article emphasizes the importance of focusing on core assets in A-shares and Hong Kong stocks, as the market is anticipated to undergo a significant style shift due to the recovery of traditional core assets [3] - The deep-sea technology sector is recognized as a strategic emerging industry, with government support expected to accelerate its development, similar to the low-altitude economy and commercial aerospace sectors [6][9] - Investment opportunities in the deep-sea technology industry are identified across the entire supply chain, including upstream core components, midstream equipment, and downstream operations and services [6] - The article suggests that the deep-sea technology sector could open up a new trillion-level market, driven by both market and policy catalysts [6][9] - The focus on stable earnings and low-valuation themes is recommended, particularly in low-tier consumption, AI+ themes, and commercial aerospace [3][9] - The potential risks include intensified U.S.-China friction, geopolitical conflicts, and domestic policy implementation falling short of expectations [4][10]